MedTrace Logo

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

NCT03831711 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-12-13

Study results available
· View outcomes & findings →

Summary

This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.

Conditions

  • Breast Carcinoma
  • Estrogen Receptor Positive

Interventions

DRUG

Gallium Ga 68-labeled GRPR Antagonist BAY86-7548

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

DEVICE

Investigational software and coils in PET/MR scan

General Electric (GE) Healthcare non-approved PET scanner coils and software

Sponsors & Collaborators

  • General Electric

    collaborator INDUSTRY

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei Iagaru · Stanford Cancer Institute Palo Alto

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-19
Primary Completion
2021-11-15
Completion
2021-11-15
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831711 on ClinicalTrials.gov